Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.

Preisser F, Bandini M, Nazzani S, Mazzone E, Marchioni M, Tian Z, Chun FKH, Saad F, Briganti A, Haese A, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Oncol. 2019 Mar 28. pii: S2588-9311(19)30035-5. doi: 10.1016/j.euo.2019.03.003. [Epub ahead of print]

PMID:
31411975
2.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
3.

Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.

Gayet M, Mannaerts CK, Nieboer D, Beerlage HP, Wijkstra H, Mulders PFA, Roobol MJ.

Eur Urol Focus. 2018 Mar;4(2):228-234. doi: 10.1016/j.euf.2016.07.007. Epub 2016 Aug 4.

PMID:
28753781
4.

The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.

Wang J, Abudurexiti M, Shao N, Wei Y, Zhu Y, Ye DW.

Eur Urol Focus. 2018 Sep 11. pii: S2405-4569(18)30243-8. doi: 10.1016/j.euf.2018.08.024. [Epub ahead of print]

PMID:
30217630
5.

Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.

Gandaglia G, Fossati N, Zaffuto E, Bandini M, Dell'Oglio P, Bravi CA, Fallara G, Pellegrino F, Nocera L, Karakiewicz PI, Tian Z, Freschi M, Montironi R, Montorsi F, Briganti A.

Eur Urol. 2017 Oct;72(4):632-640. doi: 10.1016/j.eururo.2017.03.049. Epub 2017 Apr 12.

PMID:
28412062
6.

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM.

Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16.

7.

Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.

Lughezzani G, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, Fossati N, Lista G, Larcher A, Abrate A, Mistretta A, Bini V, Palou Redorta J, Graefen M, Guazzoni G.

Eur Urol. 2014 Nov;66(5):906-12. doi: 10.1016/j.eururo.2013.12.005. Epub 2013 Dec 16.

PMID:
24361258
8.

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.

Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, Shariat SF, Montorsi F, Saad F, Briganti A, Karakiewicz P.

Eur Urol Oncol. 2018 Sep;1(4):314-320. doi: 10.1016/j.euo.2018.04.013. Epub 2018 May 15.

PMID:
31100253
9.

A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM.

Eur Urol. 2015 Sep;68(3):464-70. doi: 10.1016/j.eururo.2014.10.021. Epub 2014 Oct 27.

PMID:
25454615
10.

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA.

Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20.

PMID:
27108162
11.

Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.

Coley RY, Zeger SL, Mamawala M, Pienta KJ, Carter HB.

Eur Urol. 2017 Jul;72(1):135-141. doi: 10.1016/j.eururo.2016.08.005. Epub 2016 Aug 11.

PMID:
27523594
12.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

13.

Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.

Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y; Canary Prostate Active Surveillance Study Investigators.

Eur Urol. 2017 Sep;72(3):448-454. doi: 10.1016/j.eururo.2016.11.017. Epub 2016 Nov 23.

PMID:
27889277
14.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2015 Jul;68(1):139-46. doi: 10.1016/j.eururo.2014.08.010. Epub 2014 Aug 20.

15.

External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients.

Hueting TA, Cornel EB, Somford DM, Jansen H, van Basten JA, Pleijhuis RG, Korthorst RA, van der Palen JAM, Koffijberg H.

Eur Urol Oncol. 2018 Oct;1(5):411-417. doi: 10.1016/j.euo.2018.04.016. Epub 2018 Jun 28.

PMID:
31158080
16.

Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy.

Chen R, Xie L, Xue W, Ye Z, Ma L, Gao X, Ren S, Wang F, Zhao L, Xu C, Sun Y; Chinese Prostate Cancer Consortium.

Urol Oncol. 2016 Sep;34(9):416.e1-7. doi: 10.1016/j.urolonc.2016.04.004. Epub 2016 May 12.

PMID:
27185342
17.

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.

Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, Shariat SF, Chun FK.

Eur Urol. 2013 Feb;63(2):201-9. doi: 10.1016/j.eururo.2012.07.030. Epub 2012 Jul 20.

PMID:
22854248
18.

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Culp SH, Schellhammer PF, Williams MB.

Eur Urol. 2014 Jun;65(6):1058-66. doi: 10.1016/j.eururo.2013.11.012. Epub 2013 Nov 20.

PMID:
24290503
19.

Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.

Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DF.

Cancer. 2013 Nov 15;119(22):3992-4002. doi: 10.1002/cncr.28303. Epub 2013 Sep 4.

20.

The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.

Klein EA, Chait A, Hafron JM, Kernen KM, Manickam K, Stephenson AJ, Wagner M, Zhu H, Kestranek A, Zaslavsky B, Stovsky M.

Eur Urol. 2017 Dec;72(6):942-949. doi: 10.1016/j.eururo.2017.03.025. Epub 2017 Apr 7.

PMID:
28396176

Supplemental Content

Support Center